Teikoku Pharma initiates trial for DMTS in Alzheimer's-related agitation
Teikoku Pharma USA is evaluating the efficacy of Dexmedetomidine Transdermal Systems for treating agitation in Alzheimer's patients.
Asset / Drug
Drug and asset intelligence for Teikoku with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.